公开(公告)号：US20250134884A1

公开(公告)日：2025-05-01

申请号：US18926048

申请日：2024-10-24

Applicant: LUMISTAR BIOTECHNOLOGY, INC. ,  ACADEMIA SINICA

Inventor： Chia-Ning SHEN ,  Edward Po-Fan CHU ,  Jen-Chieh CHENG ,  Yu-Fen CHANG ,  Wan-Chi SU ,  Min-Wen CHUNG

IPC: A61K31/496 ,  A61P3/10

Abstract: A method for treating Type II diabetes. The method involves administering to a subject a pharmaceutical composition comprising an effective amount of a 5-HT1A receptor antagonist. The pharmaceutical composition comprises an effective amount of a 5-HT1A receptor antagonist, and pharmaceutically acceptable carriers thereof.

公开(公告)号：US20240190866A1

公开(公告)日：2024-06-13

申请号：US18282219

申请日：2022-03-11

Applicant: Academia Sinica

Inventor： Wei-Chieh CHENG ,  Wei-An CHEN ,  Yu-Hsin CHEN ,  Ting-Jen CHENG ,  Chia-Ning SHEN ,  Chiao-Yun HSIEH ,  Pi-Fang HUNG

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61P35/00

Abstract: Disclosed herein are novel polyhydroxylated indolizidine and pyrrolizidine derivates and methods for using the same in the treatment of cancer. The present polyhydroxylated indolizidine and pyrrolizidine derivates has the structure of formula (I),




wherein: X is O or b and c are independently an integral of 0 or and 1; R is selected from the group consisting of H, C1-6 alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, heteroaralkenyl, beteroaralkynyl, heterocyclyl, alkoxy, aryloxy, and sulfonyl.

公开(公告)号：US20180244713A1

公开(公告)日：2018-08-30

申请号：US15754806

申请日：2016-08-26

Applicant: Academia Sinica

Inventor： Wen-Shan LI ,  Wen-Chun HUNG ,  Chia-Ning SHEN

IPC: C07J43/00 ,  C07J41/00 ,  C07J9/00 ,  C07J63/00 ,  C07J73/00 ,  A61P35/00

CPC classification number: C07J43/003 ,  A61P35/00 ,  C07J9/005 ,  C07J41/0005 ,  C07J41/0055 ,  C07J63/00 ,  C07J63/004 ,  C07J73/003 ,  C07J73/005

Abstract: Disclosed herein are novel sialyltransferase inhibitors, and compositions and methods for treating diseases and/or conditions associated with the activation of sialyltransferase, such as a cancer, an immune disease or an inflammatory disease.